Small Molecule API Market to exhibit 5% CAGR between 2022 and 2031

Increasing demand of high potency drugs and increasing cases of chronic diseases are expected to boost small molecule active pharmaceutical ingredient (API) Market. In a study, Future Market Insights (FMI) has forecast the small molecule API market to exhibit 5% CAGR between 2021 and 2031. According to the report, although in-house manufacturing is currently leading the market, the trend towards outsourcing in the pharmaceutical industry makes outsourced production more lucrative. The outsource segment is therefore likely to account for 50% of production in the market during the forecast period.

A small molecule drug can enter cells easily because it has a low molecular weight. Once inside the cells, it can affect other molecules, such as proteins, and may cause cancer cells to die. Increasing research on small molecule APIs and novel Biologics APIs will boost the market growth. High potency drug market is a growing pharmaceutical segment. Increasing prevalence of cancer and other chronic diseases owe to the need of oncology drugs and antibody drug conjugates.

The oncology market is growing enormously. High potency drugs constitute significantly to the new drugs that are under development. Small molecule demand still dominates the API market, however new biological entity demand is also growing rapidly growing healthcare expenditure is resulting in new molecule discovery, the evaluation of various molecules for possible disease treatment, and the adoption of an innovative approach to these studies.

As increasing prevalence of chronic disorders like cardiovascular diseases, diabetes, cancer and infectious diseases, and increasing research on small molecule APIs will boost the market growth. Besides this, government funding to API manufacturing units is also increase in developing countries like India, Israel, and China. In May 2020, AstraZeneca recovered the global rights to brazikumab from Allergan. Small molecule monoclonal antibody is developed for Crohn’s Disease and Ulcerative Colitis and adds to their growing presence in Immunology

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-4591

Coronavirus pandemic has changed the public medical care needs and spending however this is viewed as transient effect on the Small Molecule API market. The immense COVID-19 patient pool attracted spotlight on the treatment of these patients, in turn increasing the demand for small molecule API.

Key Takeaways from Small Molecule API Market Study

  • As a result of increasing healthcare spending and favorable reimbursement policies, the U.S. accounts for over 87% of North America small molecule API market
  • Rising focus on health and wellness will enable the U.K. exhibit a little below 4% y-o-y growth in 2021
  • Germany will account for maximum sales in Europe. Besides this, the demand from France too is expected to rise
  • Increasing investment in research and development within pharmaceutical will drive sales in China

 “The market is highly competitive, compelling the key players to aim at strategic partnerships. Some of the leading players have been focusing on strategic collaborations to expand their footprint and portfolio” says the FMI Analyst

The use of external resources (people, equipment and/or expertise) to facilitate the preparation of Active Pharmaceutical Ingredient (API) or advanced intermediates has become a common practice for most pharmaceutical development organizations. In early development the reasons to seek external support for the manufacture of API was attributed to a number of factors, including a lack of sufficient internal capacity, a need to source unique technical expertise or a desire to achieve overall cost reductions.

For organizations which have no internal GMP manufacturing capabilities whatsoever (e.g. biotech companies), outsourcing is, of course, a necessity. However, companies which have some level of internal manufacturing capacity may have options to use outsourcing to their strategic advantage. This outsourcing capability has increase the source of generating more revenue for new emerging companies. For fast growth of industry they follow outsourcing strategies.

In addition, key players in the Small Molecule API market are keenly focusing on carrying out strategic activities such as advance technology for manufacturing, acquisitions, in order to create a strong position into the market is leading into vigorous developments which is helping the market to grow at a considerable rate.

For Instance, In January 2020, Novartis acquisition of operations of Aspen in Japan. This acquisition strengthened Sandoz’s position in world market of off-patent medicines and generic drugs manufacturing.

Key Participant InsightsVarious manufacturers are undergoing partnerships, collaborations, acquisitions and distribution agreements to improve their market footprint.

For Instance, in December 2020, Pfizer Inc. and PostEra announced a strategic partnership with the goal of accelerating small molecule drug discovery by developing a platform technology based on generative chemistry.

Also, in January 2020, Merck announced its strategic collaboration for oncology platform with Taiho Pharmaceutical Co, Ltd. And Taiho Pharmaceutical Co, Ltd to expand its focus on small molecule inhibitors for cancer research.

Key players in the Small Molecule API market are focusing on developing novel drugs due to its demand across various therapeutic area. Some of the key players are , Hoffmann-La Roche Ltd, Albany Molecular Research Inc., AstraZeneca, Merck & Co, Inc., BASF SE, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Novartis AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, GILEAD Science Inc.,

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4591

Want more insights?Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Small Molecule API market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on Small Molecule API market on basis of Molecule by (Standard API, High Potency API), By Production (In-House, Out Source),Application (Clinical, Commercial), Therapeutic Area (Cardiovascular Diseases, Respiratory Disorders, Infectious Diseases, Metabolic Disorders, Oncology, Immunology, Neurology, Urology, Dermatology , Ophthalmology , General Health, Others) across seven major regions.

Small Molecule API Market by CategoryMolecule Type

  • Standard API
  • HPAPI

Production

  • Captive/In-House
  • Out Source

Application

  • Clinical
  • Commercial

Therapeutic Area

  • Cardiovascular Diseases
  • Respiratory Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology
  • Immunology
  • Neurology
  • Urology
  • Dermatology
  • Ophthalmology
  • General Health
  • Others

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa (MEA)
  • Oceania

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-4591

Organoids Market By Application, By End User and By Region, Industry Analysis, Revenue Opportunity, Competitive Analysis

The Global Organoids market study provides critical information related to the global, regional and top players including Organoids market share analysis, winning strategies, recent developments, and financial planning. Besides providing information regarding the key players in the Organoids market, the study also recalibrates, the impact of macroeconomic and microeconomic factors that has the potential to impact the growth of the Organoids market.

Over the past decade, healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-8106

Understanding the Impact of Covid-19 on Healthcare Industry

With the pandemic plaguing maximum countries across the globe, healthcare industry is witnessing its fair share of ‘ups and downs’. The COVID-19 has placed an enormous strain on the healthcare sector’s workforce, facilities and infrastructure. Despite the endless pressure, healthcare sector is growing at a moderate pace due to the improvement in infrastructure and advancement in technology, healthcare sector is delivering a healthy performance.

The FMI’s latest report on the Organoids market gives a detailed analysis on the impact of COVID-19 with an incisive coverage on the innovative strategies adopted by the market players to survive the challenges due to pandemic.

Reasons to Buy the report

We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

Any Queries About Report, Contact Us @ https://www.futuremarketinsights.com/askus/rep-gb-8106

Organoids Market: Segmentation

By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Detailed analysis on the geographical region and country wise insights are offered in the latest Organoids market report with established market players as well as incumbents in the region.

The global Organoids market can be segmented as follows:

By Product Type, Organoids market is segmented as:

  • Intestinal Organoids
  • Hepatic Organoids
  • Pancreatic Organoids
  • Colorectal Organoids
  • Neural Organoids
  • Others

By Application, Organoids market is segmented as:

  • Bio-banking
  • Biomedical Research and Drug Discovery
  • Regenerative Medicine
  • Cancer Research
  • Therapeutic Tools
  • Others

By End User, Organoids market is segmented as:

  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Academics and Research Institutes

Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.

Competitive Analysis 

By Prominent Market Players:

  • Cellesce Ltd
  • DefiniGEN
  • Qgel
  • Hubrecht Organoid Technology (HUB)
  • OcellO B.V.
  • STEMCELL Technologies Inc.

With an extensive SWOT analysis, the FMI’s study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Organoids market

Request For Table of Content @ https://www.futuremarketinsights.com/toc/rep-gb-8106

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Why Future Market Insights?

Comprehensive analysis on evolving purchase pattern across different geographies
Detailed insights of market segments and sub-segments for historical as well as forecast period
A competitive analysis of prominent players and emerging players in the Organoids market
Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Pharmacovigilance Market By Product Type, By End User and By Region: Industry Analysis, Revenue Opportunity, Competitive Analysis

ESOMAR-certified company Future Market Insights (FMI) has published a report on the global pharmacovigilance market for the forecast period 2021-2031. According to the report, the market is poised to reach new heights, as pharmaceutical companies scramble to introduce new drug candidates for multiple ailments, which will result in an increase in clinical trials.

As per FMI’s analysis, the market is expected to register double-digit growth, experiencing an impressive CAGR throughout the forecast period. Historically, the market posted credible gains, surpassing US$ 6 billion in 2020, expanding at a CAGR of over 14%. Growth prospects were further heightened during the COVID-19 pandemic, as the scramble for new treatment approaches is prompting pharmaceutical companies to initiate clinical trials for the same.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1107

Prominent pharmaceutical companies are forging long-term partnerships and service agreements with contract research organizations and business processing outsourcing units to enhance existing pharmacovigilance operations by virtue of cost reduction from drug delivery to post-marketing approvals. In April 2021, Thermo Fisher Scientific Inc. announced its plans to acquire Pharmaceutical Product Development (PPD) Inc. for a purchase price of US$ 17.4 billion, which will help enhance the latter’s pharmacovigilance portfolio expansion.

Key Takeaways from FMI’s Pharmacovigilance Market Study

  • By phase of drug development, stage IV clinical trials pharmacovigilance solutions account for over 3 out of 4 applications
  • Based on method type, targeted spontaneous reporting to make maximum use of pharmacovigilance solutions
  • By service provider type, contract outsourcing to generate almost two out of five pharmacovigilance solutions uptake
  • US experiencing robust pharmacovigilance solutions providers presence amid prevalence of good PV practices
  • Forthcoming clinical trials for numerous drug candidates through 2021 to widen UK’s growth prospects
  • India to emerge as an emerging pharmacovigilance hub amid growing trends of medical operations outsourcing
  • China to experience growth on the back of recent amendments to render pharmacovigilance implementation stronger

Key Players:

  • Accenture Plc.
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions
  • Covance Inc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc.
  • ICON Plc
  • iGATE Corporation
  • iMED Global Corporation
  • inVentiv Health Inc.
  • Novartis AG
  • PAREXEL International Corporation
  • Pfizer Inc.
  • Pharmaceutical Product Development LLC. (PPD)
  • PRA Health Sciences Inc.
  • Quintiles Transnational Holdings Inc.
  • Sanofi SA
  • Synowledge LLC
  • Wipro Ltd.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1107

Competitive Landscape

Prominent pharmacovigilance solutions providers are relying on collaborating with prominent biopharmaceutical and pharmaceutical companies to offer their digital solutions to facilitate effective patient care solutions. Also, offering advanced solutions is another prominent strategy. Some prominent faces include F. Hoffmann- La Roche, GlaxoSmithKline Plc., Covance Inc., ICON Plc. and iGATE Corporation among others.

Covance Inc. is a prominent pharmacovigilance solutions providing, offering end-to-end PV services spanning clinical and post-marketing phases from medical contract centers to ICSRs to medical reviews to electronic regulatory submissions. The system helps track weekly, daily and monthly metrics for quality, productivity and efficiency.

In April 2020, ICON Plc. initiated efforts to enhance pharmacovigilance practices, considering the onset of COVID-19. A webinar conducted on this issue by the company called for key pharmaceutical companies to automate their workflows by installing proactive and dedicated intelligence processes, forging detailed business and continuity plans and a virtually globally distributed footprint.

Pharmacovigilance Market – Key Segments Covered

Phase of Drug Development

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Type of Methods

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Service Type Provider

  • In-house Pharmacovigilance
  • Contract Outsourcing

Geography

  • North America (US and Canada)
  • Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe)
  • Asia-Pacific (China, India, ASEAN, Japan and Rest of APAC)
  • Latin America (Brazil, Mexico and Rest of LATAM)
  • Middle East & Africa (GCC, South Africa and Rest of MEA)

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1107

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Smart Insulin Pens Market 2022 End-User Demand by Types, Regions, Top Players, Service Provides, Regional Outlook and Forecast to 2031

ESOMAR-certified consulting firm Future Market Insights (FMI) projects the global smart insulin pens market is likely to surpass the billion dollar mark by 2021, expanding at a positive CAGR, as per a newly published research report. A stupendous double digit growth rate has been predicted for the market in the long-run. Growing preference for non-invasive treatment and the ever widening diabetes burden are likely to steer the market in a forward direction.

According to FMI’s report, the market posted significant gains in the past, with Bluetooth smart insulin pens generating over 30% of the revenue share in 2017. Also, according to the International Diabetes Federation, presently, just under half a billion people are living with diabetes worldwide, and their number is projected to increase by 25% in 2030, and 51% by 2045 respectively.

Manufacturers, therefore, are leveraging these trends to introduce novel and innovative product lines, enabling them to secure a firm footing in the market. In November 2020, for instance, Medtronic launched its InPenTM smart insulin device equipped with real-time GuardianTM Connect CGM Data- the first smart insulin pen for diabetics on multiple daily injections. Recently, in April 2021, BioCorp and Roche Diabetes Care launched the Mallya smart insulin pen device in France.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1827

Key Takeaways from FMI’s Smart Insulin Pens Market Report

  • By connectivity, Bluetooth connected smart insulin pens to account for over half of the revenue share by 2031
  • By indication, type 2 diabetes treatment to account for the bulk of smart insulin pens deployment
  • Retail pharmacies were the primary distribution channels for smart insulin pens, e-commerce sales spiking rapidly
  • US to experience credible growth amid increasing approval rates for new diabetes management devices
  • Growing preference for needle-free insulin injections to widen adoption across the UK
  • Germany & France to experience increased collaborations between key manufacturers in the long-run
  • Large concentration of regional level manufacturers to pivot growth across India and China

Smart Insulin Pens Market – Key questions answered in the report

  • What trends are in store for the smart insulin pens market growth?According to FMI, the global smart insulin pens market is likely to register a multi-billion dollar valuation in the short and long-run forecasts, attributed to a general increase in the global diabetic population pool and the consequent increase in hospital workload. Demand for Bluetooth connected smart insulin pens is expected to remain especially high
  • Which is the most promising smart insulin pens market?As per FMI’s analysis, demand for smart insulin pens are expected to remain high across the US market, attributed to unceasing efforts by the government to eradicate the diabetes epidemic by virtue of extensive advertising campaigns. Additionally, India and China are expected to emerge as the dominant markets in the Asia-Pacific region, characterized by the presence of numerous regional level manufacturers

Which prominent players operate in the global smart insulin pens market?

  • Digital Medics Pty Ltd.,
  • Emperra GmbH e-Health Technologies,
  • Companion Medical Inc.,
  • Sanofi Aventis LLC,
  • Novo Nordisk A/S,
  • Eli Lily and Company,
  • Companion Medical,
  • Diabnext,
  • Jiangsu Delfu Medical Device Co. Ltd.,
  • DIAMESCO Co Ltd.,
  • Patients Pending Ltd (Bigfoot Biomedical Inc.),
  • BERLIN-CHEMIE

are some major smart insulin pens manufacturers profiled in FMI’s report

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1827

Competitive Landscape

Major insulin pens manufacturers are effectively leveraging major expansion strategies, ranging from new product launches and R&D to collaborating with existing manufacturers or outright/partial acquisition of key market players. A major emphasis is being laid on incorporating virtual technological advancements to enhance diabetes management.

In February 2021, Novo Nordisk and the University of Toronto announced a CAD 40 million investment deal to establish the Novo Nordisk Network for Healthy Populations. This network will focus on new approaches to address diabetes and aid in chronic disease prevention. This will likely help broaden smart insulin pens development.

Companies are also focusing on providing advanced software platforms, such as Digital Medics’ DiabetesPlus DataSync Software. This platform enables users to download insulin and glucose data directly from the device. Key features include downloading insulin data from the insulin pen, glucose levels from the glucose meter and synchronization of data on the Cloud for use with mobile devices.

According to FMI’s report, the following insulin pens manufacturers currently operate in the global market:

  • Digital Medics Pty Ltd.
  • Emperra GmbH e-Health Technologies
  • Companion Medical Inc.
  • Sanofi Aventis LLC
  • Novo Nordisk A/S
  • Eli Lily and Company
  • Diabnext
  • Jiangsu Delfu Medical Device Co. Ltd.
  • DIAMESCO Co Ltd.
  • Patients Pending Ltd (Bigfoot Biomedical Inc.)
  • BERLIN-CHEMIE

Smart Insulin Pens Market – Key Segments Covered

Indication

  • Diabetes Type I
  • Diabetes Type II

Connectivity

  • Bluetooth Connected
  • USB Connected

Distribution Channel

  • Clinics & Ambulatory Surgical Centers
  • E-Commerce
  • Retail Pharmacies

Region

  • North America (US and Canada)
  • Europe (Germany, UK, France, Spain, Italy and Rest of Europe)
  • Asia-Pacific (India, China, Australia & New Zealand, Japan and Rest of APAC)
  • Rest of the World (Brazil, Mexico, GCC and South Africa)

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1827

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Ophthalmic Eye Drops Market to rise at above 5% CAGR between 2022 and 2031

Increasing number of post-operative eye infections, emergence of new pathogens and poor eye hygiene practices are increasing the prevalence of eye infections worldwide. With the incidence unlikely to reduce anytime soon, Future Market Insights (FMI) in a study has reported the demand for ophthalmic eye drops to rise at above 5% CAGR between 2021 and 2031.

The National Ambulatory Medical Care Survey indicated that Americans made more than 4 million visits to ambulatory physicians for bacterial conjunctivitis in 2005. Approximately 70% of patients with acute conjunctivitis present to primary and urgent care providers, which accounts for 1% of all primary care office visits. Adenoviruses account for 65 to 90% of cases of viral conjunctivitis.

The soaring cases of eye infections have been driving ophthalmic eye drops sales. While the report presents positive outlook for growth, ongoing restrictions amid COVID-19 outbreak might hamper sales.

COVID-19 pandemic is expected to negatively impact the ophthalmic eye drops market. Significant reduction in physician office visits and subsequent decline in the number of prescriptions and OTC eye drop purchases are expected to hamper the market growth during the COVID-19 pandemic. Speedy vaccination programs against COVID are expected to enable market recovery in the coming 1-2 years.

New eye drop product launches, branded as well as generic, are expected to be hampered in the short term due to disruptions in the supply chain, delayed pipeline research and development and shift in the priority of leading healthcare companies to COVID-19 vaccine and treatment developments.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13140

According to the report, institutional sales of ophthalmic eye drops will rise considerably in the coming years. It will account for over half of ophthalmic eye drops sold through the forecast period.

Key Takeaways from Ophthalmic Eye Drops Market Study

  • Ophthalmic eye drops market will expand consistently to surpass a valuation of US$ 15 Bn by 2021
  • The U.S. holds over 92.1% share of the North American market, but Canada is projected to expand faster at around 4.0% CAGR
  • Rising cases of eye infection will drive sales in the U.K., enabling it register 3.9% y-o-y growth in 2021
  • Rising willingness to spend on advanced eye care will drive sales in Germany and France
  • Expansion of the healthcare sector will emerge as chief growth driver in China and Japan. Both countries will exhibit high demand for dilation drops

“Increasing prevalence of eye infections, technological advancements, and high risk of infections from increasing use of contact lens are expected to boost the growth of the ophthalmic eye drops market.” says the FMI Analyst

Due to their increasingly active lifestyle and desire for better aesthetics, many people are shifting to contact lenses. However, many ocular infections are associated with the use of contact lenses. Each year in the United States, approximately 1 million eye infections occur related primarily to keratitis, a fungal infection of the cornea, and contact lens infections account for estimated direct costs of $175 million. In addition, 40.9 million U.S. adults wear contact lenses, and 99% of 4,269 contact-lens wearers were reported at least one contact lens – related hygiene behavior associated with an increased risk for eye infection or inflammation. Nearly a million eye infections requiring a trip to the doctor happen each year, many of them related to contact lens use.

Who is Winning?The top players are focusing on increasing acquisitions at the regional level. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires other players to possess well-established products and solutions that are expected to become a good revenue source for the acquirer. Acquisitions also enable the company to enter new emerging markets as well as enhance their presence in existing markets. Furthermore, key market players such as Novartis and Gerresheimer AG are focusing on the expansion of their market reach in different regions. For example-

  • In November 2020, Gerresheimer Regensburg announced that it is expanding its production area in Germany. The company has planned the expansion of its production capacity in small batch production, as a result of increasing development projects for pharmaceutical and medical technology products.
  • In November 2019, Sandoz announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited, strengthening its position in the world’s third largest generics market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13140

Some of the key market players covered by FMI include Novartis AG, Bausch & Lomb, Akorn, Inc., Biomedica, AdvaCare Pharma, C2 PHARMA, Kraeber GmbH, Iskon Remedies, HANSHIN GROUP, Berry Global Inc., Nolato AB, Bormioli Pharma, WG Pro-Manufacturing Inc., Gerresheimer AG, Adelphi Healthcare Packaging, Aptar Group Inc., and Amcor Plc.

Ophthalmic Eye Drops Market by CategoryDrug Class

  • Anesthetic Drops
  • Dilation Drops
  • Glaucoma Drops
  • Steroid Drops
  • Antibiotic Drops
  • Others (Antihistamine, Lubricants Tear Drops)

Indication

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Eye Infection
  • Retinal Disorders
    • Macular Degeneration
    • Diabetic Retinopathy
    • Others
  • Uveitis
  • Others

Drug Formulation

  • With Preservative
  • Preservative Free

Container Type

  • Single Dose Container
  • Multiple-Dose Container

Distribution Channel

  • Institutional Sales
    • Hospitals
    • Community Clinics
    • Ophthalmic Clinics
    •  Public Health Agencies
    • Veterinary Hospitals & Clinics
  • Retail Sales
    • Retail Pharmacies
    •  Drug Stores

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/13140

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Subcutaneous Drug Delivery Market 2022 Outlook, Current and Future Industry Landscape Analysis 2028

Subcutaneous drugs are injected in the layer of the skin called the cutis, which comprises the epidermis and dermis. The subcutaneous parenteral route of drug delivery is effective for administrating vaccines and for sustained release drugs and for insulin, goserelin etc. Numerous pharmaceutical products are marketed and being developed for various diseases which are administered through subcutaneous routes. Drug manufactures are also majorly focusing on packaging and effective delivery options for easy administration process so as the drug can be introduced into the patient with reliability. As many pharmaceutical company are developing self-administered drugs, several subcutaneous drug delivery devices have witnessed high adoption rate. Due to this findings major opportunities now exist for innovative approaches to subcutaneous drug delivery devices for many leading players in subcutaneous drug delivery market. Subcutaneous drug delivery market is growing as various advance drug delivery devices are introduced in market such as Jet injectors, Auto injectors, Mechanical pumps etc. The subcutaneous drug delivery systems are broadly used by the end users due to the easy and reliable operating mechanism, thus generating large revenues in the subcutaneous drug delivery market. On the other hand, subcutaneous drug delivery market is gaining profit as conventional intravenous drugs are being replaced by subcutaneous drugs. The rapid technological advancement in subcutaneous injectable devices is attributed due to wearable patch pumps and wearable smart patch as they are prefilled and have thin needles, accommodates high dose volumes and flexible to use. The global subcutaneous drug delivery market is expected to witness a significant growth over the forecast period due to rising prevalence of diabetes across the globe.

To remain ‘ahead’ of your competitors, request for a sample

Subcutaneous Drug Delivery Market: Drivers and Restraints

As per WHO 422 million of adult population have diabetes in the US which represents significant population and with increasing diagnosis rate subcutaneous drug delivery market further expected witness growth. Increasing treatment seeking rate and spreading awareness about possible treatment options for diabetes is expected to fuel the subcutaneous drug delivery market. Due to self-administered drug, administration of injectable moves increasingly from practitioner offices and healthcare facilities to patient homes. As subcutaneous route of administration is effective alternative to intravenous route of administrations it is expected to future drive the growth of subcutaneous drug delivery market. With the advent of single injector device, auto injector, mechanical pumps and progress in digital medicine, it is anticipated to growth in the subcutaneous drug delivery market. Also, technical advancement like Bluetooth connectivity of glucometer also digital display and touch screen features in devices are expected to boost the demand for subcutaneous drug delivery technology market during the forecast period. Whereas, high cost of this devices may hamper the growth Subcutaneous Drug Delivery market.

Subcutaneous Drug Delivery Market: Overview

Many biological drugs such as monoclonal antibodies, protein based therapeutics are under clinical trials and subcutaneous route of administration is being investigated for their administration this is expected to contribute significantly to Subcutaneous Drug Delivery market growth. Based on product type, fillable injectors registers the highest revenue share in the subcutaneous drug delivery market owing to their reusability coupled with its less price and growing demand from patients. As high demands for the combination of innovative drug- device product such as Insulin pumps and Omnipod from Insulet from diabetic patients have contributed majorly in the growth of the market. Owing to this players are exploring new possibilities for developments in drug formulations and delivery device technology for subcutaneous drug delivery. The growing adoption rate of this subcutaneous drug delivery systems is expected to fuel the demand for the subcutaneous drug delivery market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-7676

Subcutaneous Drug Delivery Market: Regional Outlook

On the basis of geography, global paraffin physical therapy market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest shares in the global subcutaneous drug delivery market due to presence of leading manufacturer and advanced healthcare infrastructure. North America is the most lucrative Subcutaneous Drug Delivery market. Europe is expected to be second most lucrative Subcutaneous Drug Delivery market due to higher treatment seeking rate. Asia-Pacific is regarded as emerging Subcutaneous Drug Delivery market due emerging economies such as India and China coupled with improving awareness among general population about treatment options. Latin America remains least lucrative Subcutaneous Drug Delivery market due to lowest adoption of Subcutaneous Drug Delivery as a treatment option.

Subcutaneous Drug Delivery Market: Key Players

Some of the global key participants operating in subcutaneous drug delivery market are: Insulet Corporation, Becton Dickinson Company, Consort Medical, West pharmaceuticals services Inc., Ypsomed AG, Elcam Medical, Sc Pharmaceuticals Inc., Steady Med Ltd, Amgen Inc., Sensile medical AG and others. 

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on: 

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Indication

Value Chain

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/7676

Regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain)

Eastern Europe (Poland, Russia)

Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Subcutaneous Drug Delivery Market: Segmentation

Global Subcutaneous Drug Delivery market can be segmented on the basis of Product type, Usability, Technology and Distribution channel.

Based on the Product type Subcutaneous Drug Delivery market is segmented as

Fillable Injectable

Prefilled Injectable

Based on the usability type Subcutaneous Drug Delivery market is segmented as:

Disposable subcutaneous drug delivery injectable

Reusable subcutaneous drug delivery injectable

Based on the Technology type Subcutaneous Drug Delivery market is segmented as:

Jet

Spring

Gas

Based on the Distribution Channel Subcutaneous Drug Delivery market is segmented as:

Hospital Pharmacies

Retail Pharmacies

Drug store

Online Pharmacies

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current, and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

Intra-Abdominal Infection Treatment Market Key Players – Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories

Some of the major vendors operating in the global intra-abdominal infection treatment market are Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories, Merck & Co., Roche Holding AG, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson., Sanofi SA., Boehringer Ingelheim GmbH, Eli Lilly and Company and others. 

The global intra-abdominal infection treatment report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Intra-abdominal infection are group of infections occurring within the abdominal cavity and vary from appendicitis, peritonitis, diverticulitis, cholecystitis, cholangitis, to pancreatitis characterized by high risk of complication resulting in high mortality despite treatment. According to the Infectious Diseases Society of America (IDSA), Intra-abdominal infection generally extends beyond the organ of origin into the abdominal cavity and is associated with an abscess. Intra-abdominal infections are associated with symptoms such as epigastric pain radiating to the back, vomiting, posterior penetrating ulcer, nausea, decreased appetite and others.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7709

Intra-Abdominal Infection Treatment Market: Drivers and Restraints

The high prevalence of intra-abdominal infection coupled with the high mortality rates generate a large inelastic demand for the intra-abdominal infection treatment market. Appendicitis is the most common cause of Intra-abdominal infection resulting in more than 300,000 cases each year and over 1 million hospital days. In 2016 about 12.3 million cases of appendicitis were recorded in the U.S. resulting in more than 340,000 surgeries and about 54,870 deaths. Globally about 7.5% of people have appendicitis at some point in their life. Mortality rates associated with intra-abdominal infections vary from 3.5% with early infection to more than 60% with well-established infection with multiple organ failure. The high mortality rate of intra-abdominal infections is exemplified by peritonitis which have a mortality rate of about 10% when treated properly. Growing geriatric population is another driver of the intra-abdominal infection treatment market as risk of developing intra-abdominal infection and mortality increases with age. The mortality rate for intra-abdominal infection rises to about 40 % in the elderly.

The increasing exposure to bacteria such as staphylococci, Pseudomonas, Candida and Enterococci owing to rising pollution, urbanization is another driver of the intra-abdominal infection treatment market. Rowing resistance to antimicrobials such as penicillin and related beta-lactam antibiotics is another driver of the intra-abdominal infection treatment market value as this necessitates use of expensive antibiotics such as piperacillin, imipenem, ticarcillin, or ciprofloxacin. Diverticulosis affects more than 10% to 25% of the elderly and is the second leading cause of infection-related mortality in the intensive care units. The growing menace of hospital and surgical acquired infections is a strong driver of the intra-abdominal infection treatment market. Almost 157,500 cases of surgical acquired infections were recorded in the United States per year resulting in approximately 8,205 deaths according to the center for disease control and prevention. Surgical acquired infections account for 11% of all deaths in intensive care units in the U.S. and account for a whopping $3.2 billion in attributable cost per year according to the center for disease control and prevention 2018 surgical acquired infections updates.

However, the increasing fragmentation of the market owing to penetration of generics is exerting a pricing pressure on the intra-abdominal infection treatment market. The excessive production capacity of antimicrobials is another cause expected to hamper the intra-abdominal infection treatment market.

Intra-Abdominal Infection Treatment Market: Overview

The global market for intra-abdominal infection treatment is expected to expand owing to growing incidence and the owing to growing stringency of regulations. For example, the Hospital Readmissions Reduction Program (HRRP) established under the Affordable Care Act, penalize hospitals with higher-than-expected readmissions. Under the HRRP, hospitals can incur a penalty of up to 3% of their Medicare payments. The intra-abdominal infection treatment market trends include a definite shift in favor of developing regions of Asia Pacific, such as India and China.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7709

Intra-Abdominal Infection Treatment Market: Regional Wise Outlook

The global intra-abdominal infection treatment market can be classified into the following region: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America, led by the U.S., is expected to account for the largest share in the global intra-abdominal infection treatment market, owing to the large demand, large healthcare expenditure, and large per capita income in the region.

The Asia Pacific intra-abdominal infection treatment market excluding Japan is projected to expand and dominate the scene in the near future, owing to the growing healthcare and healthcare expenditure. China and India are anticipated to account for the major share of the Asia Pacific intra-abdominal infection treatment market growth. Germany, France and the U.K., are projected to be the largest drivers of the Europe intra-abdominal infection treatment market. The Middle East and Africa intra-abdominal infection treatment market is anticipated to be dominated by the gulf economies of Saudi Arabia, Kuwait, UAE and Qatar.

The intra-abdominal infection treatment report covers exhaustive analysis on,

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain 

Regional analysis includes,

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Intra-Abdominal Infection Treatment Market: Segmentation 

To gain a bird’s eye view of the global intra-abdominal infection treatment market, the report is segmented on the basis of drugs, pathogens, infection type, distribution channel, end users and region.

Based on the drugs, the global intra-abdominal infection treatment market can be segmented as,

  • Antibiotics
  • Anti-bacterials
  • Antifungals
  • Analgesics
  • Others

Based on the pathogens, the global intra-abdominal infection treatment market can be segmented as,

  • Gram-positive
  • Staphylococcus
  • Enterococcus
  • Streptococcus
  • Others
  • Gram-negative
  • Bacteroides
  • Clostridium
  • Proteus
  • Klebsiella
  • Pseudomonas
  • Enterobacter
  • coli
  • Others

Based on the infection type, the global intra-abdominal infection treatment market can be segmented as,

  • Community-acquired
  • Healthcare associated

Based on the distribution channel, the global intra-abdominal infection treatment market can be segmented as,

  • Institutional Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on the end users, the global intra-abdominal infection treatment market can be segmented as,

  • Hospitals
  • Clinics
  • Home Settings

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7709

Report Highlights: 

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

Muscle Oxygen Monitors Market Industry Analysis, Opportunities, Technology, Demand, Top Players and Growth Forecast 2028

Based on application type , muscle oxygen monitors market has been segmented into muscle oxygen profile , heart rate profile and bicycle speed . Measurement of muscle oxygen level is the main application of muscle oxygen monitors, hence, muscle oxygen profile is expected to share the highest revenue in muscle oxygen monitors market. Based on the technology, the market has been segmented into three different softwares, which are used to display different types of data.Muscle Oxygen Monitors: Market Insights 

Moxy Muscle Oxygen Monitors measures and monitors the oxygen saturation levels in muscle tissue of athletes. Muscle Oxygen Monitors are based on a technology which is called as Near-Infrared Spectroscopy. It is a kind of spectroscopy method which uses infrared region of the spectrum. The “Near Infrared” uses light that is at or just beyond the red end of the visible spectrum. Muscle oxygen monitors uses light from about 680 nm to about 800 nm. Near infrared light is used in the process of muscle oxygen monitoring because it can travel a very long distance through skin, muscle and fats. It does not get completely absorbed through skin and hence, travels through a long distance. The light is scattered through the tissues rather than travelling in a straight line and helps in making quantifiable measurements. The other factor why infrared region is used is that it gets absorbed by haemoglobin and myoglobin molecules which have oxygen bound to them.

Myoglobin is a molecule in muscle cells which is capable of binding and releasing oxygen and acting as a store of oxygen in the muscle.

Haemoglobin is the molecule in red blood cells which is responsible for the transportation of oxygen in the blood. Haemoglobin binds oxygen while passing through lungs and then releases the oxygen when it passes through the capillaries of the tissue that needs it.

Oxygen saturation in the muscles refers to the percentages of haemoglobin and myoglobin which carries oxygen in the muscles. It is derived by taking the amount of oxygen carried by haemoglobin and myoglobin which is then divided by the total amount of haemoglobin and myoglobin. The results obtained is then multiplied by hundred to get it as a percentage.

The muscle oxygen monitors can measure the oxygen saturation percentage which can vary from zero percent to hundred percent. Muscle oxygen monitors performs a secondary measurement of total amount of haemoglobin.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8026

Muscle Oxygen Monitors : Market Dynamics

Increase in the occurrence of sports activities is expected to increase the use of muscle oxygen monitors. Muscle oxygen monitors are very easy to carry because of their light weight. This can drive the muscle oxygen monitors market. Muscle oxygen monitors have many features like wireless charging, data storage etc., hence, technological advancements in the device can be a major driver of muscle oxygen monitors market. Accuracy of muscle oxygen monitors is the main feature which can increase the growth of muscle oxygen monitors. The problems associated with the muscle oxygen monitors like leakage, aspiration problems can restrain the growth of muscle oxygen monitors market.

Muscle oxygen Monitors Market: Region-wise Outlook

On the basis of geography, muscle oxygen monitors market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest revenue shares in the global muscle oxygen monitors market primarily due to high technological advancement in the field of healthcare and enhanced healthcare infrastructure . US is expected to have high revenue share in muscle oxygen monitors because of the high number of sports activities. Europe is expected to show high revenue share in the muscle oxygen monitors market due to increased R &D expenditure for manufacturing healthcare products.

Muscle Oxygen Monitors Market: Key Players

Some of the key players present in global muscle oxygen monitors market are humon, Moxy Monitor, Oxford Optronix Ltd., BSX Insight, Medtronic,

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8026 

Muscle Oxygen Monitors Market: Segmentation

The Muscle oxygen monitors market is segmented by application, technology and region.

Segmentation by Application Type

  • Muscle Oxygen Profile
  • Heart rate Profile
  • Bicycle Speed

Segmentation by Technology

  • Peripedal Software
  • Perfpro Software
  • TrainingMate Software

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-8026

Long Term Post-Acute Care Software Market 2022: Drivers and Restraints, Regional Wise Outlook, Key Players, Segmentation, Forecast to 2028

Primary revenue drivers of the Long Term Post-Acute Care Software market are early onset of rapid ageing and rapid rise in baby boomer population. Rising incidence of chronic illnesses across countries is another important factor fuelling the adoption of long term post-acute care software across institutions for better healthcare management purpose. There are cases where the rise in internet penetration rates are driving organizations to adopt these long term post-acute care software. Every market comes with a silver lining though. Restraints of the long term post-acute care software market include need for skilled manpower to operate the machines, high prices of the software, lack of skilled nursing staff, faltering reimbursement rates for long term stays, etc. Overall, increasing attention towards patient record maintenance and need for meaningful patient outcome are factors estimated to create ongoing demand for long term post-acute care software across the globe.Long Term Care (LTC) patients consist of elderly people who need continuous monitoring of healthcare conditions. These patients need monitoring post-acute care. This type of software helps to maintain or store records regarding patient health information due to treatment or post treatment in any healthcare delivery setting. Long Term Post-Acute Care Software helps to maintain data on patient demographics, medical history, past problems, medications administered, progress notes, recurrent problems, vital signs, immunization history, laboratory data, and radiology reports. Use of the long term post-acute care software helps to automate and streamline the clinician’s workflow. This type of Long Term Post-Acute Care Software helps to generate full record of patient’s treatment journey in clinical settings alongside other supporting care-related activities and evidence-based decision support, quality management, and outcomes reporting. 

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8103

Long Term Post-Acute Care Software Market: Overview

The global market for Long Term Post-Acute Care Software is very niche with a handful of solutions currently approved and available. Increased focus towards personalized therapies coupled with attention towards evidence-based outcome are factors estimated to impact the revenue growth of the Long Term Post-Acute Care Software Market. Developed markets are estimated to account for the largest revenue potential as compared to emerging markets due to high internet penetration rates and availability of improved technology. Developing product and process know-how and improvement in decision sciences are factors projected to support the demand for Long Term Post-Acute Care Software. Revenues from Long Term Post-Acute Care Software market is estimated to expand at an impressive CAGR over the forecast period wherein revenues derived from developed markets could outweigh the market value share of emerging markets for the long term post-acute care software.

Long Term Post-Acute Care Software Market: Regional Wise Outlook

Geographically, the Long Term Post-Acute Care Software Market is segmented into eight regions viz. North America, Latin America, Western Europe, Asia-Pacific Excluding China and Japan, Eastern Europe, Japan, China, Middle East and Africa. The North America market is estimated to account for significant market value share due to presence of large number of managed care organizations and assisted living facilities. An ageing population and large incidence of chronic illnesses are factors expected to lead to revenue increase in Western European markets –projected to emerge as second largest market for Long Term Post-Acute Care Software. Markets in Asia Pacific region are expected to develop rapidly and create significant demand for long term post-acute care software in various healthcare settings.

Long Term Post-Acute Care Software Market: Key Players

Some of the major players in the global Long Term Post-Acute Care Software Market are Allscripts Healthcare Solutions, Inc., Epic Systems Corporation, Cerner, McKesson Corporation, Omnicare, Omnicell, Inc., MatrixCare, Optimus EMR, Netsmart, and PointClickCare., Strategic initiatives such as divestments and M&A activities define the long term post-acute care software market.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology Matrix
  • Value Chain

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8103

Regional analysis of the Long Term Post-Acute Care Software market report includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Rest of Western Europe)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan and China (India, Australia & New Zealand, ASEAN, Rest of APEJC)
  • Japan
  • China
  • Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Long Term Post-Acute Care Software Market: Segmentation 

Tentatively, the global Long Term Post-Acute Care Software Market has been segmented on the basis of product type, application type, end user and geography.

Based on product type, the global Long Term Post-Acute Care Software market is segmented as:

  • Clinical Software
  • Non-clinical Software

Based on application, Long Term Post-Acute Care Software market is segmented as:

  • Financial Data Management and Billing
  • Electronic Health Record Management
  • Home Healthcare Management
  • ALF &ILF
  • Others

Based on end users, the global Long Term Post-Acute Care Software market is segmented as:

  • Hospitals
  • Clinics and Nursing Homes
  • Managed Care Organizations
  • Assisted Living Facilities
  • Home Healthcare
  • Others

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-8103 

Long Term Post-Acute Care Software Market Report Highlights:

  • Overview of Global Healthcare and Healthcare IT Market
  • Evolution of the technology
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.

Radiation-Induced Myelosuppression Treatment Market is projected to top US$ 3.5 Billion in 2028

[207 Pages Report] Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2022 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Report tracks key factors driving revenue growth of the market –

  • Increasing prevalence of cancers
  • Early diagnosis, promising improved chances of positive outcomes
  • Fostering R&D funds supporting cancer research
  • Strong product pipeline
  • Bolstering adoption of chemo-radiotherapy in cancer treatment

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

  • Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
  • Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars – Epogen and Neupogen, and Neulasta respectively.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape.  The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8116

Radiation-Induced Myelosuppression Treatment Market by Category

Indication: 

  • Neutropenia
  • Anemia
  • Thrombocytopenia

Drug Class:

  • Growth factors
  • Erythropoietin stimulating agents
  • Thrombopoietic agents
  • Iron supplements

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Drug stores

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-8116